Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.35 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.35 |
| ▸ | RARB | P10826 | 3/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.34 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL533740 | 0.83 | MMP9 (0.38) | MMP9MMP8MMP13LMNAPOLB | |
| SCHEMBL3504560 | 0.83 | FAAH (0.41) | MMP9MMP8MMP13LMNAPOLB | |
| SCHEMBL534408 | 0.81 | SLC2A1 (0.40) | MMP9MMP8MMP13LMNAPOLB | |
| SCHEMBL13164734 | 0.79 | MAPK1 (0.47) | MMP9MMP8MMP13LMNAPOLB | |
| SCHEMBL533781 | 0.79 | TP53 (0.56) | MMP9MMP8MMP13LMNAPOLB | |
| SCHEMBL15908216 | 0.76 | MMP9 (0.38) | MMP9MMP8MMP13LMNAPOLB | |
| SCHEMBL533766 | 0.75 | LMNA (0.43) | LMNATP53TSHRPLA2G4BRARB | |
| SCHEMBL2016511 | 0.74 | NPC1 (0.42) | LMNATP53S1PR1S1PR3S1PR5 | |
| SCHEMBL15908236 | 0.74 | SLC2A1 (0.40) | MMP9MMP8MMP13LMNAPOLB | |
| SCHEMBL2019737 | 0.70 | CNR1 (0.46) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9169187-B2 | Method of making peptides using diphenylmethane compound | AJINOMOTO CO., INC. (JP) | 2015-10-27 | — | — | US | disclosed |
| US-20140213761-A1 | DIPHENYLMETHANE COMPOUND | AJINOMOTO CO., INC (JP) | 2014-07-31 | — | — | US | disclosed |
| EP-2415745-A1 | DIPHENYLMETHANE COMPOUND | Ajinomoto Co., Inc. (JP) | 2012-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213761-A1 | DIPHENYLMETHANE COMPOUND | CCKAR, VIP, CCKBR | MMP9 3657/4885MMP8 4073/4885MMP13 3898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.